comparemela.com
Home
Live Updates
Sanofi - Aventis Groupe: Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis : comparemela.com
Sanofi - Aventis Groupe: Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis
Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis A median annualized bleeding rate
Related Keywords
Israel
,
Tel Aviv
,
Eva Schaefer Jansen
,
Corentine Driancourt
,
Felix Lauscher
,
Nathalie Pham
,
Sally Bain
,
Gili Kenet
,
Priya Nanduri
,
Global Head Of Development
,
International Society On Thrombosis
,
Alnylam Pharmaceutical Inc
,
Nasdaq
,
Euronext
,
International Society
,
Israeli National Hemophilia Center
,
Sheba Medical Center
,
Amalia Biron Thrombosis Research Institute
,
Tel Aviv University
,
Chief Medical
,
On Demand Factor Concentrates
,
Bypassing Agents
,
Breakthrough Bleeds
,
Two Phase
,
Targeting Antithrombin
,
Antithrombin Levels
,
Thrombin Generation
,
Alnylam Pharmaceutical
,
Private Securities Litigation Reform Act
,
Statement Regarding Forward Looking
,
Sanofi
,
Eventis
,
Roupe
,
Dress
,
Release
,
Fitusiran
,
Prophylaxis
,
Educed
,
Leeds
,
People
,
Hemophilia
,
Without
,
Inhibitors
,
Ompared
,
Rior
,
Factor
,
Bypassing
,
Agent
,
comparemela.com © 2020. All Rights Reserved.